A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
Reynolds, Kerry Lynn
Bedard, Philippe L (Toronto, ON Canada)
Lee, Se-Hoon (Seoul, Republic of Korea)
Lin, Chia-Chi (Taipei, Taiwan)
Tabernero, Josep (Hospital Universitari Vall d'Hebron)
Alsina, Maria (Hospital Universitari Vall d'Hebron)
Cohen, Ezra (La Jolla, CA USA)
Baselga Torres, Josep, 1959-2021, (New York, NY USA)
Blumenschein, George (Houston, TX USA)
Graham, Donna M. (Toronto, ON Canada)
Garrido-Laguna, Ignacio (Salt Lake City, UT USA)
Juric, Dejan (Fruit Street, Boston, MA 02114 USA)
Sharma, Sunil (Salt Lake City, UT USA)
Salgia, Ravi (Duarte, CA USA)
Seroutou, Abdelkader (Basel, Switzerland)
Tian, Xianbin (East Hanover, NJ USA)
Fernandez, Rose (East Hanover, NJ USA)
Morozov, Alex (New York, NY USA)
Sheng, Qing (Cambridge, MA USA)
Ramkumar, Thiruvamoor (East Hanover, NJ USA)
Zubel, Angela (Basel, Switzerland)
Bang, Yung-Jue (Seoul, Republic of Korea)
Universitat Autònoma de Barcelona

Date:	2017
Abstract:	Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. Secondary objectives were to characterize safety/tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. This open-label, dose-finding study comprised dose escalation, followed by expansion in patients with squamous cell carcinoma of the head and neck or esophagus, and HER2-overexpressing metastatic breast cancer or gastric cancer. During dose escalation, patients received LJM716 intravenous once weekly (QW) or every two weeks (Q2W), in 28-day cycles. An adaptive Bayesian logistic regression model was used to guide dose escalation and establish the RDE. Exploratory pharmacodynamic tumor studies evaluated modulation of HER3 signaling. Patients received LJM716 3-40 mg/kg QW and 20 mg/kg Q2W (54 patients; 36 patients at 40 mg/kg QW). No dose-limiting toxicities (DLTs) were reported during dose-escalation. One patient experienced two DLTs (diarrhea, hypokalemia [both grade 3]) in the expansion phase. The RDE was 40 mg/kg QW, providing drug levels above the preclinical minimum effective concentration. One patient with gastric cancer had an unconfirmed partial response; 17/54 patients had stable disease, two lasting >30 weeks. Down-modulation of phospho-HER3 was observed in paired tumor samples. LJM716 was well tolerated; the MTD was not reached, and the RDE was 40 mg/kg QW. Further development of LJM716 is ongoing. registry number NCT01598077 (registered on 4 May, 2012). The online version of this article (10. 1186/s12885-017-3641-6) contains supplementary material, which is available to authorized users.
Note:	Altres ajuts: This study was funded by Novartis Pharmaceuticals Corporation (study design,collection, analysis, and interpretation of data, and medical editorial writing assistance).
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	HER3 ; HER2 ; LJM716 ; Monoclonal antibody ; Phase I
Published in:	BMC Cancer, Vol. 17 (september 2017) , ISSN 1471-2407

DOI: 10.1186/s12885-017-3641-6
PMID: 28899363

11 p, 542.8 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles